Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907397 · ClinicalTrials.gov registry record · Phase 2
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
A Phase 2 study of Food Allergy and Peanut Allergy, sponsored by Scott Sicherer.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT03907397 is a Phase 2 study of Food Allergy and Peanut Allergy that has completed, run by Scott Sicherer. The registered enrollment target is 73 participants, below the 960-participant average among 17 other Food Allergy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03907397, a Phase 2 study of Food Allergy and Peanut Allergy, has completed, sponsored by Scott Sicherer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind, placebo-controlled oral food challenge \[DBPCFC\]) will be associated with attaining even higher thresholds over time in children with high threshold peanut allergy compared to those avoiding peanut. The secondary clinical objectives include assessing the development of sustained unresponsiveness (SU, a surrogate term for tolerance without daily ingestion), effects on quality of life, and safety compared to those avoiding peanut. Additionally, this study will phenotype the allergic response to peanut based on threshold and response to exposure. Mechanistic study objectives will determine the immune and molecular basis of the high threshold endotype, identify predictors of response to exposure, and determine mechanisms and biomarkers of remission.
Conditions Studied
Interventions
- BIOLOGICAL Peanut Protein
- OTHER Continued peanut avoidance
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907397
The ClinicalTrials.gov registry entry for NCT03907397 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 960-participant average among 17 other Food Allergy trials with a reported enrollment target (92% lower). The listed sponsor is Scott Sicherer, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Food Allergy appearing as the primary indexed condition, and to 2 interventions - of which Peanut Protein is the first listed.
NCT03907397 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03907397 about?
NCT03907397 is a clinical study titled "Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy". The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind, placebo-controlled oral food challenge \[DBPCFC\]) will be associated with attaining e...
What is the current status of trial NCT03907397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2019-08-05. Estimated completion is 2023-11-17.
What conditions does trial NCT03907397 study?
This clinical trial studies the following conditions: Food Allergy, Peanut Allergy.
What interventions are being tested in trial NCT03907397?
The interventions under investigation include: Peanut Protein (BIOLOGICAL), Continued peanut avoidance (OTHER).
Who is sponsoring clinical trial NCT03907397?
This trial is sponsored by Scott Sicherer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03907397 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Omalizumab Weight-Based Dosing Efficacy Trial
RECRUITING · Phase 2
-
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
COMPLETED · Phase 2
-
Multi Immunotherapy to Test Tolerance and Xolair
COMPLETED · Phase 2
-
Preventing Anaphylaxis With Acalabrutinib
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.